the development of hypomagnesemia was investigated retrospectively in 25 patients with malignancy treated with cisplatin containing combination chemotherapy at the first time. Serum magnesium and potassium levels were measured l day after
completion of
cisplatin infusion. The most common type of cancer was lung cancer (9 patients) followed by gastric cancer(5 patients), pancreas cancer, unknown primary cancer(2 patients, respectively) and so on. EP(etoposide, cisplatin) was the most frequently
administered regimen. Five patients had previous history of chemotherapy. While 10 patients received cisplatin dose of 80 mg/㎡(body surface area) or more, 15 patients received less than 80mg/㎡. The mean serum magnesium concentration after
chemotherapy
was 1.93±0.25mg/dl(1.5-2.6mg/dl), and 8 patients932.0%) developed hypomagnesemia(<1.9mg/dl). The incidence of hypomagnesemia showed no correlation among age of patients, dose of cisplatin, history of previous cheomotherapy and regimens of
chemotherapy.
The serum potassium concentration after chemotherapy was not statistically different compared wihtthat of before chemotherapy. There was no episode of symptomatic hypomagnesemia. In conclusion, hypomagnesemia is relatively common side effect of
cisplatin infusion, therefore, frequent measurement of serum mangnesium concentration should be mandatory in patients receiving cisplatin containing chemotherapy.
|